Hodgkin lymphoma is one of two major categories of lymphoma. It is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. A defining attribute of the Reed-Sternberg cell is its expression of the CD30 antigen. The American Cancer Society estimates that more than 9,000 people will be diagnosed with Hodgkin lymphoma in the United States during 2015.
Hodgkin Lymphoma Clinical TrialsBrentuximab vedotin phase 3 ECHELON-1 trial for frontline treatment of Hodgkin lymphoma
Randomized, two-arm trial of brentuximab vedotin plus AVD versus ABVD for frontline treatment in patients with newly diagnosed advanced classical Hodgkin lymphoma. Study #C25003
Randomized, double-blind trial evaluating brentuximab vedotin versus placebo for the treatment of patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant. Enrollment in this trial is complete. Study #SGN35-005